Category

Archives

CRM1

Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series

36 views | Jul 15 2022

Guillermina Remaggi et al. thought that selinexor might help to address an important clinical need in the treatment of patients with relapsed/refractory MM. [Read the Full Post]

Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells

24 views | Jul 14 2022

Amal Alzahrani et al. confirmed that the combination of Selinexor with RG-7388 could induce a caspase-mediated apoptotic mechanism via up-regulation of p53 and p21. [Read the Full Post]

PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia

171 views | Nov 25 2021

Inge Govaerts et al. thought that the antileukemic effect of PSEN1-selective gamma-secretase inhibition could be synergistically enhanced by the addition of other targeted inhibitors. [Read the Full Post]

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells

0 views | Nov 24 2021

Md Hafiz Uddin et al. found that KPT-8602 with or without olaparib reduced homologous recombination-regulated DNA damage response targets including BRCA1, BRCA2, CHEK1, EXO1, BLM, RAD51, LIG1, XRCC3 and RMI2. [Read the Full Post]

Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

270 views | Aug 22 2021

Ajai Chari et al. suggested that in addition to more frequent dose reductions, prompter and more aggressive supportive care might have contributed to the low discontinuation rate, longer duration therapy, and greater efficacy rates observed in the MSSM cohort. [Read the Full Post]

Neurocytological Advances in the Treatment of Glioblastoma Multiforme

236 views | Aug 22 2021

Brian Fiani et al. discussed the recent neurocytological treatment strategies for GMB and the results of the studies. [Read the Full Post]

The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia

322 views | Dec 07 2020

Delphine Verbeke et al. demonstrated that KPT-8602 enhanced the effects of dexamethasone to inhibit B-ALL and T-ALL cells via NR3C1- and E2F-mediated transcriptional complexes, allowing to achieve increased dexamethasone effects for patients. [Read the Full Post]

Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma

284 views | Dec 06 2020

Joel G Turner et al. found that inhibition of exportin 1 with selinexor synergistically sensitizeed human multiple myeloma to melphalan by inhibiting Fanconi anemia pathway-mediated DNA repair. [Read the Full Post]

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

261 views | Jul 30 2020

Panagiotis Malandrakis et al. showed that selinexor was a new anti-myeloma drug that seemed to be effective in patients who had no other therapeutic options, including patients who had received novel cellular therapies such as CAR-T cells. [Read the Full Post]

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

264 views | Jul 30 2020

Isabel Jiménez et al. highlighted the pathogenic role of the innate immune microenvironment in PCNSL and provided pre-clinical evidence for the development of selinexor and ibrutinib as a new promising therapeutic option with cytotoxic and immunomodulatory potential. [Read the Full Post]